首页> 外文期刊>Clinical ophthalmology >A prospective 3-year follow-up trial of implantation of two trabecular microbypass stents in open-angle glaucoma
【24h】

A prospective 3-year follow-up trial of implantation of two trabecular microbypass stents in open-angle glaucoma

机译:在开角型青光眼中植入两个小梁微旁路支架的前瞻性三年随访研究

获取原文
           

摘要

Purpose: To evaluate 3-year safety and intraocular pressure (IOP) following two trabecular microbypass stents in phakic and pseudophakic subjects with open-angle glaucoma (OAG) not controlled on preoperative medication. Patients and methods: In this prospective pilot study, phakic or pseudophakic subjects with OAG and IOP between 18?mmHg and 30?mmHg on one preoperative topical ocular hypotensive medication underwent medication washout. Thirty-nine qualified subjects with preoperative unmedicated IOP ≥22?mmHg and ≤38?mmHg received two stents. Postoperative examinations were scheduled at Day 1, Week 1, Months 1, 3, 6, and 12, and semiannually through Month?60. Ocular hypotensive medication was considered if postoperative IOP exceeded 21?mmHg. IOP, medication use, and safety were assessed at each visit. Subject follow-up through Month 36 was completed. Results: Thirty-six eyes (92.3%; 95% confidence interval [CI] 79.1%, 98.4%) achieved the primary efficacy end point of Month 12 reduction in IOP ≥20% from baseline (unmedicated IOP) without ocular hypotensive medication. Four subjects required medication during the Month 36 follow-up period. Mean IOP at 36?months for subjects not taking medication was 15.2?mmHg. At 36?months, subjects sustained mean IOP decrease of 9.1±2.7?mmHg (95% CI 8.0?mmHg, 10.14?mmHg), or 37% IOP reduction, from unmedicated baseline IOP. Compared to preoperative medicated IOP, subjects had mean reduction at Month 36 of 5.5±2.7?mmHg (95% CI 4.5?mmHg, 6.6?mmHg), or 26% reduction. Both measures of IOP reduction were highly significant ( P <0.001). Other than one case of early postoperative hyphema that resolved at 1?week, no postoperative adverse events were attributed to stent implantation. Conclusion: In a pilot study, two trabecular microbypass stents to treat OAG subjects on one preoperative medication provided statistically significant, sustained, and safe reduction of IOP to ≤15?mmHg without medication through 36?months.
机译:目的:评估在未接受术前药物治疗的开角型青光眼(OAG)的有晶状体和假晶状体患者中,两个小梁微旁路支架术后的三年安全性和眼内压(IOP)。患者和方法:在这项前瞻性先导研究中,对一种术前局部降眼压药物中OAG和IOP在18?mmHg和30?mmHg之间的有晶状体或假晶状体受试者进行了药物冲洗。术前未经药物治疗的IOP≥22?mmHg和≤38?mmHg的三十九名合格受试者接受了两个支架。术后检查安排在第1天,第1周,第1、3、6和12个月,每半年一次至第60个月。如果术后眼压超过21?mmHg,则考虑使用降压药。每次访视时评估IOP,药物使用和安全性。通过第36个月的受试者随访已完成。结果:三十六只眼(92.3%; 95%置信区间[CI] 79.1%,98.4%)达到第12个月的主要疗效终点,而未使用眼压降压药使IOP较基线(未药物IOP)降低了≥20%。在第36个月的随访期间,四名受试者需要药物治疗。未服用药物的受试者在36个月时的平均IOP为15.2mmHg。在36个月时,受试者的平均IOP较未用药的基线IOP降低了9.1±2.7?mmHg(95%CI 8.0?mmHg,10.14?mmHg),或IOP降低了37%。与术前加药的IOP相比,受试者在第36个月的平均降低幅度为5.5±2.7?mmHg(95%CI为4.5?mmHg,6.6?mmHg),或降低了26%。两种降低IOP的措施均具有高度显着性(P <0.001)。除了1例在术后1周即可解决的早期术后前房积血,没有术后不良事件归因于支架植入。结论:在一项前期研究中,在术前用两种小梁微旁路支架治疗OAG受试者,在不使用药物的情况下,在36个月内,统计学上显着,持续且安全地将IOP降至≤15mmHg。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号